Health & Fitness Delta variant and behavior caused vaccine efficacy drop, NY DOH says
'Most mutated Covid variant so far' may already be EXTINCT
Professor Francois Balloux, a geneticist at University College London, said the C.1.2 variant 'shows no evidence of increasing in frequency, and it may be extinct by now.'Concerns were raised that the mutant strain — dubbed C.1.2 — could be more infectious than other variants and better able to evade vaccines.
The Delta variant and changes in human behavior - such as the end of masking and social distancing - may explain whyvaccines became less effective at protecting New Yorkers against infection, a new study from the state's Department of Health (DOH) finds.
DOH scientists used statewide immunization, testing, and hospitalization datasets to examine vaccine effectiveness trends during New York's Delta surge over summer 2021.
Results showed that efficacy against infection declined for the Pfizer-BioNTech,and vaccines by as much as 25 percent.
Now WHO warns of threat of 'Mu' variant found in Colombia
The World Health Organization has declared the variant 'Mu' or B.1.621 as a possible threat. Almost 50 cases have been spotted in the UK, and hundreds in the US.The mutant strain — which also has the scientific name B.1.621 — was first detected in Colombia in January.
Despite decreased effectiveness for infection, the study foun the vaccines remained highly protective against hospitalization with Covid - with effectiveness over 90 percent for adults ages 18 to 64 during the Delta surge.
Only New Yorkers over age 65 saw a slight decline in the vaccines' protection against hospitalization over the summer - which the team says support the need for booster shots in older adults.
These data suggest that 'ongoing waning protection may be less of a current concern for adults younger than 65 years,' said DOH scientist Dr Eli Rosenberg.
Booster shots have spurred endless confusion and debate in the U.S. in recent weeks.
The Centers for Disease Control and Prevention (CDC) and Food and Drug Administration (FDA) recentlyfor seniors and other Americans deemed at high risk for breakthrough Covid.
Cases of the Mu variant rise, experts fear variant evades vaccines
The Mu variant has appeared in 49 of 50 U.S. states, as the variant begins to impact the country just as the Delta variant falters. The Colombian still is far from dominant in the states.Mu was first discovered in Colombia in January, and has since been detected in 41 countries, including the U.S. and the U.K.
Later this week, the FDA's advisory committee on vaccines will discuss similar booster shot authorizations for Moderna's and Johnson & Johnson's vaccines.
In part, these discussions are complicated because the U.S. hason how well the vaccines are working - and who is at most risk for a breakthrough case.
The CDC is not comprehensively tracking all breakthrough infections, focusing instead on severe cases and specific groups, such as healthcare workers.
As a result, many booster shot discussions have used data from Israel and the UK - two countries that are tracking breakthrough infections more closely. But these nations' populations and vaccine rollouts are very different from the U.S.
A new study from the New York DOH helps to fill this data gap and suggests why the state saw a rise in breakthrough infections this summer.
The study - which is not yet peer reviewed - wason October 9.
Hispanics and younger adults more likely to contract Delta variant
Adults between ages 18 and 44 accounted for more than half of positive Delta specimens at 55.3% compared to other age groups while Hispanic Americans made up 39.4% of infections.Researchers from the Centers for Disease Control and Prevention (CDC) found that the variant accounted for 95 percent of Covid cases that underwent genome sequencing at Kaiser Permanente Southern California (KPSC) as of July 21.
'This latest study conducted by our renowned scientists here at DOH is the largest to examine in-depth changes in vaccine effectiveness over time broken down by all three COVID-19 vaccines types currently authorized for use in the United States,' said New York Health Commissioner Dr Howard Zucker, a senior author, in a.
'It clearly demonstrates what we've been saying all along – getting a COVID-19 vaccine continues to be the best way out of this pandemic, and the best way for New Yorkers to prevent serious illness and hospitalization.
'We urge all New Yorkers to remain vigilant and get vaccinated against COVID-19 if you have not already done so.'
The DOH scientists linked several statewide datasets with information on New Yorkers' Covid vaccinations, test results, and hospitalizations in order to compare vaccine effectiveness over the course of 2021.
In addition, the researchers compared vaccine effectiveness by age, by which vaccine patients received, and by their vaccination timing.
Video: NHS plead with pregnant women to get jab after low uptake stats (Daily Mail)
Don't assume Delta is most contagious Covid variant, SAGE warns
Both Alpha and Delta sparked explosions in cases when they emerged in the UK. SAGE scientists said there was 'no reason' to assume that this would not happen again.Both Alpha and Delta sparked an explosion in infections when they emerged in the UK, forcing ministers to impose restrictions or delay plans to lift controls.
Vaccination timing is particularly crucial in studies like this one, because some past research on Covid antibodies has suggested that vaccines could lose their effectiveness over time.
In total, the study included about 8.8 million adults living in New York - of whom about two-thirds were fully vaccinated.
The researchers focused their analysis between May 1 and August 28, 2021, during which the Delta variant went from accounting for two percent of cases in the state to 99 percent of cases.
Vaccine effectiveness against infection declined during the Delta surge - meaning fully vaccinated New Yorkers were more likely to have a positive Covid test during this time than they had been earlier in 2021.
For Pfizer vaccine recipients between the ages of 18 and 49, vaccine effectiveness against infection declined by 25 percent during the Delta surge.
Effectiveness declined by 19 percent for Pfizer recipients ages 50 to 64, and by 14 percent for Pfizer recipients over age 65.
Moderna vaccine recipients saw similar effectiveness declines: 18 percent decline for those ages 18 to 49, 14 percent decline for those ages 50 to 64, and nine percent decline for those over age 65.
J&J vaccine recipients also saw reduced protection from Covid infection: 19 percent decline for those ages 18 to 49, and 11 percent declines for those ages 50 to 64 and over 65.
New Delta subvariant will be dominant in Britain in January
According to the Sanger Institute, the largest variant surveillance centre in the country, AY.4.2 was responsible for 16 per cent of new cases in England in the fortnight up to November 13. Its hotspot is Torridge, Devon, where it is behind 51 per cent of infections.But its rate of growth is speeding up and experts predict it could be dominant in England as soon as January, before outpacing Delta in the rest of the UK shortly after.A Government-funded study last week found the new strain is slightly less likely to cause illness, meaning the UK could be dealing with a more manageable and mild form of Covid next year.
The researchers found similar declines in the vaccines' protection against a Covid case, regardless of when they had their shots.
This finding suggests that the immune system was not facing 'waning immunity' from reduced antibodies, the team said.
Instead, the increase in breakthrough cases was 'highly correlated' with Delta's takeover of the Covid landscape in New York state.
Once Delta fully dominated New York cases - at 85 percent prevalence - the researchers saw vaccine effectiveness plateau, further suggesting that this highly contagious variant was behind the drop.
In addition, the researchers suggested that changing Covid safety behaviors in New York may have contributed to an increase in breakthrough cases.
The study authors noted that New York followed CDC guidance early in the summer, telling fully vaccinated residents that they could go maskless in public locations.
At the same time, more New Yorkers took part in indoor dining, events, and other activities as the city reopened.
Despite decreasing vaccine effectiveness against infection, all three vaccines remained very protective against severe disease and hospitalization, the DOH study found.
For younger adults (ages 18 to 64), the vaccines were at least 90 percent effective against hospitalization throughout the Delta surge, with no significant declines over time.
Only New Yorkers over age 65 saw slight declines in the vaccines' ability to protect against hospitalization during the Delta surge.
Omicron variant mapped: Where in UK 'very high' risk strain has been identified
THE OMICRON Covid variant, first detected on November 25 by scientists in South Africa, has spread to several countries around the world so far including the UK - but where in the UK has Omicron been identified?In the UK, three cases had been reported across the nation as of Sunday, but an additional six in Scotland were confirmed on Monday.
For seniors who'd received the Pfizer vaccine, effectiveness against hospitalization dropped from 95 percent to 89 percent.
For those who received the Moderna vaccine, effectiveness dropped from 97 percent to 94 percent.
'The findings of our study support the need for boosters in older people in particular, and we encourage them to seek out a booster shot from their health care provider, pharmacy or mass vaccination site,' said DOH scientist and lead author Dr Eli Rosenberg.
'We saw limited evidence of decline in effectiveness against severe disease for people ages 18 to 64 years old.
'While we did observe early declines in effectiveness against infections for this age group, this appears to have leveled off when the Delta variant became the predominant strain in New York.
'Together, this suggests that ongoing waning protection may be less of a current concern for adults younger than 65 years.'
Pfizer applies for authorization of COVID booster for kids 16 and 17 .
The drug-maker is applied for regulatory approval from the FDA for the booster shot of their vaccine on Tuesday. It would be the first booster shot available to anyone under 18.The drugmaker applied for emergency use authorization with the Food and Drug Administration (FDA) for their booster shots in children aged 16 or 17 on Tuesday.